Stephens Investment Management Group LLC Has $68.65 Million Holdings in Repligen Corporation (NASDAQ:RGEN)

Stephens Investment Management Group LLC boosted its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 0.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 539,542 shares of the biotechnology company's stock after buying an additional 2,741 shares during the period. Stephens Investment Management Group LLC owned approximately 0.96% of Repligen worth $68,651,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after purchasing an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. increased its position in Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after purchasing an additional 594,189 shares during the last quarter. Groupama Asset Managment increased its position in Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after purchasing an additional 400,680 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Repligen in the 4th quarter worth about $53,428,000. Finally, Raymond James Financial Inc. acquired a new position in Repligen in the 4th quarter worth about $52,492,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

NASDAQ:RGEN traded down $8.24 during mid-day trading on Monday, hitting $121.96. 228,074 shares of the company's stock traded hands, compared to its average volume of 725,434. The firm has a 50 day moving average of $125.65 and a two-hundred day moving average of $139.29. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. Repligen Corporation has a 12 month low of $102.97 and a 12 month high of $182.52. The firm has a market capitalization of $6.85 billion, a price-to-earnings ratio of -272.81, a price-to-earnings-growth ratio of 3.73 and a beta of 1.11.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same quarter last year, the company earned $0.28 EPS. The company's quarterly revenue was up 10.4% on a year-over-year basis. On average, equities analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on RGEN shares. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research note on Tuesday, April 29th. Barclays started coverage on Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. Royal Bank Of Canada decreased their price target on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. Finally, JPMorgan Chase & Co. decreased their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Repligen presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.75.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.